A Historical Beginning and the Evolution of Modern Clinical Trial Design

Clinical Trials Day commemorates May 20, 1747, when Scottish physician James Lind conducted the first controlled clinical trial on 12 patients with scurvy. His use of a control group, comparing the administration of oranges and lemons, laid the foundation for the randomized controlled trial (RCT), a cornerstone of modern new drug development. The U.S. Food and Drug Administration (FDA), through its Center for Drug Evaluation and Research (CDER), is highlighting the role of the Center for Clinical Trial Innovation (C3TI), launched in April 2024, to advance the quality of clinical trials. This initiative recognizes the need for traditional clinical trial designs to evolve into more sophisticated, digitally-driven models that align with rapidly changing biotechnology and patient convenience expectations.

Regulatory Innovation Through the C3TI Demonstration Program

The FDA CDER's C3TI Demonstration Program provides close regulatory consultation to sponsor companies, enabling them to apply innovative clinical techniques in actual Investigational New Drug (IND) applications. The program focuses on three key areas: Selective Safety Data Collection (SSDC), Bayesian Supplemental Analyses, and Streamlined Trials Embedded in Clinical Practice (STEP). SSDC, which reduces unnecessary data collection in late-stage (Phase 3) trials for therapies with established safety profiles, can significantly reduce costs for pharmaceutical companies. Furthermore, Bayesian analysis, which provides multifaceted statistical validation, and STEP, which directly utilizes real-world clinical data, are considered breakthroughs in addressing the time inefficiencies of clinical trials.

Global Clinical Market Shifts and Economic Impact

The global clinical trial market is estimated to be approximately $66.3 billion in 2025, potentially reaching up to $94.2 billion, with continued annual growth, and is projected to reach approximately $175 billion by 2035. In particular, the decentralized clinical trial (DCT) market, which integrates smart devices and remote monitoring, is expected to grow rapidly, with a market size of approximately $7.3 billion to $9.9 billion in 2025 and an annual growth rate of over 10%. The FDA's C3TI initiative supports the institutionalization of these DCTs, increasing patient recruitment rates and reducing dropout rates, thereby creating economic benefits. As a result, pharmaceutical companies can reduce clinical trial attrition risk and development costs, maximizing the capital efficiency of their drug pipelines.

Realizing Patient-Centricity and Future Prospects for Biotechnology

Strict clinical protocols in the past have been a major barrier to patient participation, delaying clinical progress. However, innovative clinical designs are now realizing patient-centricity. Through STEP designs, patients can participate in trials within their routine care settings, which is expected to significantly increase participation rates among diverse populations. This increased data diversity will be a critical factor in increasing the likelihood of regulatory approval for treatments for rare diseases and in the field of precision medicine. Biotechnology companies can shorten their investment recovery periods by adopting innovative designs early and securing strategic partnerships and licensing opportunities.